

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number  
**WO 03/059346 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/415**, (74) Agents: **WEICKMANN & WEICKMANN** et al.; Postfach 860 820, 81635 München (DE).

(21) International Application Number: PCT/EP03/00504

(22) International Filing Date: 20 January 2003 (20.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02001339.7 18 January 2002 (18.01.2002) EP  
02012566.2 5 June 2002 (05.06.2002) EP

(71) Applicant (for all designated States except US): **THE GENETICS COMPANY INC.** [CH/CH]; Wagistrasse 27, CH-8952 Schlieren (CH).



(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/059346 A1

(54) Title: BETA-SECRETASE INHIBITORS

(57) Abstract: The invention relates to novel beta-secretase inhibitors.

**Beta-secretase inhibitors****Description**

5

The present invention relates to novel inhibitors of the aspartyl protease BACE (beta-secretase), to their pharmaceutical compositions and to their use for treating diseases caused by amyloid beta peptide depositions such as Alzheimer disease and Down Syndrome.

10

Alzheimer's disease (AD) is a neurodegenerative disorder clinically characterized by progressive dementia that inevitably leads to incapacitation and death. Upon autopsy, massive synaptic loss and neuronal death is observed in brain regions critical for cognitive function, 15 including cerebral cortex, entorhinal cortex, and hippocampus (reviewed R.D. Terry, E. Masliah, L.A. Hansen, The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations, in: R.D. Terry et al. (Ed.), Alzheimer Disease, Lippincott, Williams and Wilkins, Philadelphia, 1999, pp. 87-206). The inexorable loss of neurons and 20 synapses over the course of AD is responsible for the dementia that slowly robs AD patients of their memories, personalities, and eventually their lives.

25 Two characteristic brain lesions define Alzheimer's Diseases at the microscopic level: neurofibrillary tangles and beta amyloid (or neuritic) plaques. Neuritic plaques surrounded by neuronal injury are found in brains of all patients suffering from AD. The main component of these plaques is the 42 amino acid form of the amyloid-beta peptide (A beta). This peptide is neurotoxic and easily forms insoluble fibrils that aggregate into plaques. 30 The accumulation of the A beta peptide is not only a hallmark of AD but also characterizes the brains of individuals with Trisomy 21 (Down's

Syndrom), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type (HCHWA-D), and other neurodegenerative disorders.

5 The 39-42 amino acids A beta peptide is generated by proteolysis of the amyloid precursor protein (APP). Several proteases called secretases are involved in the processing of APP.

10 Cleavage of APP at the N-terminus of the A beta peptide by beta-secretase and at the C-terminus by gamma-secretase constitutes the beta-amyloidogenic pathway, i.e. the pathway by which A beta is formed. A description of the proteolytic processing fragments of APP is found, for example in Citron M., *Neurobiology of Aging* 23 (2002), 1017-1022.

15 The aspartyl protease responsible for processing of APP at the beta-secretase cleavage site was recently identified by (Vassar R. et al., *Science* (1999) 286, 735-741.). This beta-secretase has been disclosed using various nomenclature, including beta amyloid converting enzyme 1 (BACE1), Asp 2 and Memapsin 2. Importantly, BACE1 knockout mice fail to produce A beta, and present a normal phenotype. When crossed with 20 transgenic mice that overexpress APP, the progeny show reduced amounts of A beta in brain extracts as compared with control animals (Luo et al., 2001, *Nature Neuroscience* 4: 231-232). This evidence strongly supports the proposal that inhibition of beta-secretase activity and reduction of A beta in the brain provides a therapeutic method for treatment of AD and 25 other beta amyloid disorders.

30 At present there are no effective treatments of halting, preventing, or reversing the progression of Alzheimer's disease. The current therapeutics for AD are all cholinergic agents; specifically, inhibitors of acetylcholinesterase (ACHE). The basis for this approach is the fact that AD causes substantial loss of cholinergic neurons. AChE inhibitors increase the levels of acetylcholine to keep the remaining cholinergic neurons firing.

Unfortunately, this type of therapy does not stop the progressive loss of cholinergic neurons, and eventually becomes ineffective. Moreover, several neurotransmitter systems are altered in AD. A better approach would be to develop agents that affect the molecules that are responsible for the neurodegeneration. Major efforts have been made to block A beta-production and aggregation in the brain by targeting the alpha, beta or gamma secretases (See for example, Sabbagh, M. et al., *Alz. Dis. Rev.* (1997) 3, 1-19). However, BACE-1 appears to be the optimal therapeutic target because (I) it catalyzes the initial, rate limiting step in A beta production, and (II) BACE-1 knockout mice do not show any apparent phenotype.

Among the few reported inhibitors of Beta-secretase so far are substrate-based, transition state analogues. PCT application WO 01/00665 C2 entitled "Catalytically active memapsin and methods of use thereof" describes the substrate specificity of the BACE enzyme, the first peptidomimetic inhibitors (OM99-1 and OM99-2) and the crystal structure of the inhibitors complexed with the enzyme. US20020115616 entitled "Novel inhibitors of Beta Amyloid Cleavage Enzymes" also describes peptidomimetic compounds. Despite their potency, these compounds are relatively large and show poor ability to cross biological membranes. For agents to work effectively *in vivo*, the compounds must not only cross the blood-brain barrier, but they must also be taken up by cells. As they must work inside the cell, these agents should be highly selective: interference with other intracellular proteases and critical signaling pathways must be minimized.


Further BACE inhibitors are described in WO 02/08810, WO 02/02520, WO 02/02518, WO 02/02512, WO 02/02506, WO 02/02505, WO 30 02/76440 and WO 02/47671.

- 4 -

However, since Alzheimer's disease is a wide-spread disease, with about 4 million people suffering therefrom in the U.S. alone, there is a great need for effective substances to treat this disease.

5 Therefore, it was an object of the invention to provide effective beta-secretase inhibitors which should further be able to cross biological membranes.

10 According to the invention this object is achieved by a beta-secretase inhibitor of formula



15 wherein

X: represents a halogen or a moiety which is bioisosteric thereto, in particular, F, Cl, Br, I, Methyl or  $\text{CF}_3$ , preferably Cl.

20 R1: each independently represents halogen, hydroxy, cyano, trifluoromethyl, nitro, a hydrocarbon group containing 1 to 4 carbon atoms, in particular, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, which may be substituted, e.g. hydroxyalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylalkyl, sulfonylamidoalkyl, amidoalkyl, carbonoylalkyl, ureylalkyl, etc. or a moiety which is bioisosteric thereto and n = 0 to 4, preferably n = 0 to 2.


25 R2: is a connecting moiety from a group consisting of a single bond or a C1-C8 hydrocarbon group, in particular, a C1-C4 alkylene group, a C2-C8 alkenylene group, a C2-C8 alkynylene group, a C1-C4 alkylene group containing at least one heteroatom, a C2-C8 alkenylene group containing at least one heteroatom or a C2-C8 alkynylene group containing at least one heteroatom.

30 Cyc: is a carbocyclic, aryl or heterocyclic moiety.

- 5 -

R3: each independently is a group being bound to the moiety Cyc and is selected from R1 or is a aryl or heterocyclic moiety substituted by 0 to 4 moieties from R1 or a group selected from

5



and m = 0 to 8, in particular 0 to 4.

10 The beta-secretase inhibitors of the invention are characterized by the presence of a halophenyl group, in particular, a chlorophenyl group, whereby a parachlorophenyl group, a diorthochlorophenyl group as well as a dimetachlorophenyl group are preferred. The phenyl group can be further substituted, e.g. with an OH group, with a dimetachloro-ortho-hydroxy-phenyl group being preferred.

15

The group X can be in ortho, meta or para position.

20 R<sup>1</sup> preferably is C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl or an alkyl group containing a substituent, e.g. hydroxyalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylalkyl, sulfonylamidoalkyl, amidoalkyl, carbonoylalkyl, ureylalkyl, etc.

25 In the beta-secretase inhibitors of the invention a connecting moiety is bound to the chlorophenyl group consisting of a single bond, a C<sub>1</sub>-C<sub>4</sub> alkylene group, a C<sub>2</sub>-C<sub>8</sub> alkenylene group, a C<sub>1</sub>-C<sub>4</sub> alkylene group containing at least one heteroatom or C<sub>2</sub>-C<sub>8</sub> alkenylene group containing at least one heteroatom, preferably 1 to 3, more preferably 1 to 2 heteroatoms. Preferably, the one or more heteroatoms are selected from N, O and S, more preferably from N and S. Most preferred are connecting moieties R<sup>2</sup> 30 containing two N atoms. The connecting moiety R<sup>2</sup> is preferably a single bond, a -CH<sub>2</sub>-S-, -CH=N-NR<sup>8</sup>-, -C(CH<sub>3</sub>)=N-NR<sup>8</sup>-, -CH=N-CH<sub>2</sub>-, -C(CH<sub>3</sub>)=N-CH<sub>2</sub>-, -CH=CH-NR<sup>8</sup>-, -C(CH<sub>3</sub>)=CH-NR<sup>8</sup>-, -CH=N-O-, -C(CH<sub>3</sub>)=N-O-, -

- 6 -




CH = CH-S-, -C(CH<sub>3</sub>) = CH-S-, -CH = CH-CH<sub>2</sub>-, -C(CH<sub>3</sub>) = CH-CH<sub>2</sub>-, -CH = N-S-, -C(CH<sub>3</sub>) = N-S-, -CH<sub>2</sub>-NH-NH-, -C(CH<sub>3</sub>)-NH-NH-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, -C(CH<sub>3</sub>)-NH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-NH-, -C(CH<sub>3</sub>)-CH<sub>2</sub>-NH-, -CH<sub>2</sub>-NH-O-, -C(CH<sub>3</sub>)-NH-O-, -CH<sub>2</sub>-CH<sub>2</sub>-O-, -C(CH<sub>3</sub>)-CH<sub>2</sub>-O-, -CH<sub>2</sub>-NH-S-, -C(CH<sub>3</sub>)-NH-S-, -CH<sub>2</sub>-CH<sub>2</sub>-S-, -C(CH<sub>3</sub>)-CH<sub>2</sub>-S-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -C(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>-, -CH-N = N-, -C(CH<sub>3</sub>)-N = N-, -CH = N<sup>+</sup>(CH<sub>3</sub>)-NR<sup>8</sup>-, -C(CH<sub>3</sub>) = N<sup>+</sup>(CH<sub>3</sub>)-NR<sup>8</sup>-, -CH = N<sup>+</sup>(CH<sub>3</sub>)-O-, -C(CH<sub>3</sub>) = N<sup>+</sup>(CH<sub>3</sub>)-O-, -CH = N<sup>+</sup>(CH<sub>3</sub>)-S- or -C(CH<sub>3</sub>) = N<sup>+</sup>(CH<sub>3</sub>)-S- group.

R<sup>8</sup> can be hydrogen or any group as stated herein for R<sup>4</sup>.




10

The connecting moiety R<sup>2</sup> connects the halophenyl residue, in particular, a chlorophenyl residue with a further cyclic moiety. Said second cycle can be a mono- or polycycle, in particular, a polycycle condensed from of two, three or four cycles. The cyclic moiety preferably contains one or more 15 heteroatoms selected from O, N and S. Especially preferred examples of the Cyc group are

20





25












30

- 7 -













5




10



- 8 -




- 9 -



According to the invention the cyclic moiety Cyc again can be substituted with up to eight substituents, preferably up to five substituents. Examples of particularly preferred substituents on the cyclic moiety Cyc are Cl, N, 20 methyl, allyl, paraiodophenyl, NO<sub>2</sub>, CF<sub>3</sub> as well as

25



Most preferably, the beta-secretase inhibitor of the invention is selected from the following compounds:


30

- 10 -

ID 1

5


10



ID 2


15

20




ID 3

25



ID 4


30



- 11 -

ID 5


5



10


ID 6

15



20

ID 7



25 The terms used herein have the following meanings, unless stated otherwise.

The term "hydrocarbon" or "hydrocarbon group" comprises any moiety which contains at least one carbon atom and at least one hydrogen atom.

30 In particular, the term "hydrocarbon" denotes any moiety having from 1 to 30 carbon atoms and includes aromatic and aliphatic groups.

- 12 -

The term "aliphatic" or "aliphatic group" means:

-a straight chain that is completely saturated or that contains one or more units of unsaturation

5

-a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (herein after referred to as "carbocyclic"), and that has a single connection point to the rest of the molecule. Any individual ring in the bicyclic system contains three to seven ring atoms.

10 Aliphatic groups include, but are not limited to, linear or branched or alkyl, alkenyl, alkynyl groups, carbocyclic groups (e.g. methyl, ethyl, n-propyl, butyl, isobutyl, sec-buyl, pentyl, acetyl, propionyl, butyrl, benzoyl, etc.) and hybrids thereof such as cycloalkyl-alkyl, cycloalkenyl-alkyl or cycloalkyl-alkenyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.). In each aliphatic group, up to 4 carbons may be independently replaced by O, N, S, or NH.

15

20 The terms "alkyl", "alkenyl" or "alkynyl" used alone or as part of a larger moiety include both straight and branched chains, wherein up to 4 carbons may be independently replaced by O, N, S or NH. Unless otherwise stated the chain lengths of alkyl, alkenyl and alkynyl contains one to twelve carbon atoms and at least two carbon atoms and one double bond, in the case of alkenyl, and at least two carbon atoms and one triple bond, in the case of alkynyl.

25 The term "heteroatom" includes oxygen and any oxidized form of nitrogen and sulphur, and the quaternized form of any basic nitrogen.

30

- 13 -

The term "aryl" or "aryl ring" used alone or as part of a larger moiety as in "arylalkyl", "arylalkoxy" or "aryloxyalkyl" refers to monocyclic, bicyclic or tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring 5 contains three to seven ring members (e.g. phenyl, naphtyl, tetrahydronaphthyl etc.)

The term "heterocycle", "heterocyclic", "heteroaryl", "heteroaryl ring" and "heteroaromatic" alone or used in a larger moiety refers to monocyclic, 10 bicyclic or tricyclic, saturated or unsaturated ring systems having a total of five to fourteen ring members, at least one ring in the system contains a heteroatom and wherein each ring contains three to seven ring members (e.g. pyridyl, triazolyl, benzthiazolyl, thienyl, morpholinyl, quinolyl, furyl, imidazolyl, pyrazinyl, pyrimidinyl, quinoxalinyl etc.)

15

The compounds of this invention may contain one or more "asymmetric" carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomic mixtures or individual diastereomers. All such isomeric forms of these compounds are expressly included in the 20 present invention. Each stereogenic carbon may be of R or S configuration. Although specific compounds and scaffolds exemplified in this invention may be depicted in a particular stereochemical configuration, compounds and scaffolds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisaged.

25

The term "query" refers to a model or pattern which is used to search chemical compound databases to find chemical, biological and pharmacological compounds which are similar to this query.

30 The term "focused library" refers to a selection of a subset of compounds from a larger collection of chemical compounds. This can be done

- 14 -

automatically by the use of computer methods using a query and an appropriate software tool or by manual selection of compounds.

The term "common pharmacophore" refers to the general pharmacophoric representation of the binding site of one or more distinct protein class or classes e.g. aspartyl proteases, phosphodiesterases or serine protease. The common pharmacophore combines pharmacophores of different ligands of protein belonging to one or more protein classes and represents a model or pattern for possible ligands or inhibitors of the distinct protein class or protein classes.

The term "Surf2Lead" refers to a method which uses three-dimensional protein information to extract two or three dimensional pharmacophoric information from a potential or known binding site of a protein (herein after referred to as "inverse active site") (WO 02/92218 A2). The pharmacophore represents a model or a pattern to find new potential ligands or inhibitors for the specific or other similar proteins.


The term "PHACIR screening" refers to the use of binary patterns (herein after referred to as "binary fingerprints") as queries to generate a focused library (WO 02/12889 A2). The binary fingerprints can be generated from two or three dimensional pharmacophores of one or more known ligands or inhibitors or from one or more inverse active sites. By searching chemical compound databases this method leads to similar but new potential ligands or inhibitors.

The compounds of this invention may be prepared by general methods known to those skilled in the art (for further references see e.g. Houben-Weyl Methods in Organic Chemistry, 4<sup>th</sup> ed). One having ordinary skill in the art may synthesize other compounds of this invention following the technique of specification using reagents that are readily synthesized or commercially available.


- 15 -

Particularly preferred compounds are:


5




2




10




4




15




6











7











8











- 16 -













- 17 -















- 18 -























- 19 -















- 20 -









- 23 -




87




88




89




90




91




92















93















94



- 25 -





- 27 -

Each R4, R5, R6 and R7 independently represents halogen, hydroxy, cyano, trifluoromethyl, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl which may be substituted, e.g. hydroxyalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylalkyl, sulfonylamidoalkyl, amidoalkyl, 5 carbonoylalkyl, ureylalkyl, etc. or a moiety which is bioisosteric thereto.

The beta-secretase inhibitors of the invention are potent compounds, by means of which beta-secretase can be inhibited selectively and effectively. They are characterized, in particular, by IC<sub>50</sub> values of  $\leq 200 \mu\text{M}$ . Further, 10 the compounds of the invention provide new scaffolds for the development of novel drugs based on beta-secretase inhibitors.

The compounds of the invention are further characterized in that they are active in cells. In this context, compounds ID3 and ID7 are particularly 15 preferred because these are especially cell-permeable active compounds.

The compounds of the invention were identified by applying computerized screening, especially PHACIR screening, for the generation of a focused library out of a compound data base based on a combined pharmacophore. 20 In this way it is possible to discover beta-secretase inhibitors having new structures, which had not yet been presumed in the art to have such activity.

As combined pharmacophore, for example, a combination of common 25 pharmacophore for aspartyl proteases and a surface-based (surf2lead<sup>®</sup>) pharmacophore of the crystallized beta-secretase:OM922 complex can be used. For the common pharmacophore of the aspartyl proteases the active center was employed for generation of the pharmacophore. For the surf2lead approach the surface of the active center of the beta- 30 secretase:OM922 complex crystallized with inhibitor was used for generation of the pharmacophore. A query for PHACIR screening was generated from a combination of the two pharmacophores. The compounds

- 28 -

of the focused library identified by virtual screening then can be subjected to an in vitro assay, e.g. a fluorescence BACE assay, or a cellular assay in order to determine its possible inhibitory action.

5 As described above, compounds having beta-secretase inhibitory action are suitable agents for the treatment of Alzheimer's disease and other disorders characterized by beta A deposits like Down's Syndrome and HCHWA-D. The invention therefore also relates to a pharmaceutical composition comprising a beta-secretase inhibitor as described above,  
10 optionally in admixture with one or more pharmaceutically acceptable carriers, diluents and/or excipients.

The compounds of the invention are particularly suited to inhibit the formation of beta amyloid peptides from the amyloid precursor protein (APP). Thus, any condition or disease can be treated which is caused by a pathological accumulation of beta amyloid such as Alzheimer's disease, Trisomy 21 (Down's Syndrome) or Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D).

15 20 The pharmaceutical composition can be formulated for administration according to the respective demands. In particular, it can be formulated for topical, oral, transdermal, parenteral, sublingual, intranasal, intrathecal, rectal, inhalative or intravenous administration.

25 For oral delivery suitable administration forms include e.g. tablets, pills, troches, gel or capsules. For parenteral delivery e.g. administration by depot, syringe, ampoule or vial can be employed. Formulations in the form of patches, medipad, ointments or creams are suitable for topical delivery.

30 The amount of inventive inhibitor required for administration in the treatment and/or prophylaxis of a disease such as Alzheimer's disease depends on the seriousness of the condition as well as on the patient to be

- 29 -

treated. Typically, a daily dose is 0.01 mg/kg of body weight to 500 mg/kg of body weight, preferably at least 0.1 mg/kg of body weight to 50 mg/kg of body weight.

5     Besides the beta-secretase inhibitor the pharmaceutical compositions of the invention can contain one or more other active substances.

10    The invention further relates to the use of a beta-secretase inhibitor as described above for the manufacture of a drug for the treatment of diseases which are mediated by beta-secretase. The beta-secretase inhibitors are especially suited for the production of a drug for the treatment of Alzheimer's disease. The expression "treatment of a condition" as used herein refers both to the treatment of established symptoms and a prophylactic treatment, by which the occurrence of the 15    disease or particular symptoms can be avoided.

20    The invention further relates to a substance library containing at least 5, preferably at least 10, more preferably at least 50 compounds as described therein. Such library can be used especially for screening in activity tests.

25    The invention is further illustrated by the following Example.

#### Example 1

##### Fluorescence BACE assay

25

The inhibitory activity of the compounds of the invention was shown in an in vitro assay, namely a fluorescence BACE assay.

30    The assay was set up in triplicate wells of 96 well black plate. rhBACE was diluted to 1 unit/well in 100 l (PBS + 0.5% Triton-X 100, pH5). BACE enzyme (obtained from R&D systems (ca.No.931-AS), reference: Vassar et al., 1999, Science 286, 735-741) was incubated with various

- 30 -

concentrations of inhibitor compound (10 nM to 500 M) for 5 min. Reaction was started by adding peptide substrate (obtained from BACHEM (cat. No.M-2470), reference: Ermolieff et al., Biochemistry 39 (2000) 12450-56) with EDANS/Dabcyl labels. After incubation for 2 hours at 37C  
5 the results were read in fluoroplate reader at 355 nm/486 nm.


The following IC50 values were determined for the above-mentioned particularly preferred compounds:

10 ID1: IC50 = 45  $\mu$ M; ID2: IC50 = 29  $\mu$ M; ID3: IC50 = 10  $\mu$ M; ID4: IC50 = 140-170  $\mu$ M; ID5: IC50 = 53  $\mu$ M; ID6: IC50 = 39.3  $\mu$ M and ID7: IC50 = 14.4  $\mu$ M

## Claims

## 1. Beta-secretase inhibitor of formula (I)

5



10

wherein

X: represents a halogen or a moiety which is bioisosteric thereto, in particular, F, Cl, Br, I, Methyl or  $\text{CF}_3$ , preferably Cl.

15

R1: each independently represents halogen, hydroxy, cyano, trifluoromethyl, nitro, a hydrocarbon group containing 1 to 4 carbon atoms, in particular, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, which may be substituted, e.g. hydroxyalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylalkyl, sulfonylamidoalkyl, amidoalkyl, carbonoylalkyl, ureylalkyl, etc. or a moiety which is bioisosteric thereto and  $n = 0$  to 4, preferably  $n = 0$  to 2.

20


R2: is a connecting moiety from a group consisting of a single bond, or a C1-C8 hydrocarbon group such as a C1-C4 alkylene group, a C2-C8 alkenylene group, a C2-C8 alkynylene group, a C1-C4 alkylene group containing at least one heteroatom, a C2-C8 alkenylene group containing at least one heteroatom or a C2-C8 alkynylene group containing at least one heteroatom.

25

Cyc: is a carbocyclic, aryl or heterocyclic moiety.

30

R3: each independently is a group being bound to the moiety Cyc and is selected from R1 or is a aryl or heterocyclic moiety substituted by 0 to 4 moieties from R1 or a group selected from




- 32 -

and m = 0 to 8, in particular 0 to 4.


5 2. Beta-secretase inhibitor according to claim 1 having the formula

10








15

20



- 33 -



- 34 -

3. Beta-secretase inhibitor according to claim 1 or 2,  
having an IC<sub>50</sub> ≤ 200 μM.
4. Beta-secretase inhibitor according to any of claims 1 to 3,  
5 being active in cells.
5. Beta-secretase inhibitor according to claim 1-4,  
having a structure according to one of the formulas 1 to 118.
- 10 6. A pharmaceutical composition comprising a beta-secretase inhibitor  
according to any of claims 1 to 5,  
optionally in admixture with one or more pharmaceutically  
acceptable carriers, diluents and/or excipients.
- 15 7. A substance library containing at least 5 beta-secretase inhibitors  
according to any of claims 1 to 5.
8. The use of a beta-secretase inhibitor according to any of claims 1 to  
5 for the manufacture of a pharmaceutical agent for the treatment or  
20 prevention of a condition which is mediated by beta-secretase.
9. The use of a beta-secretase inhibitor according to any of claims 1 to  
5 for the manufacture of a pharmaceutical agent to inhibit the  
formation of beta amyloid peptides from the amyloid precursor  
25 protein (APP).
10. The use according to claim 8 or 9 for the manufacture of a  
pharmaceutical agent for the treatment or prevention of Alzheimer's  
disease or any disorder caused by pathological deposits of beta  
30 amyloid peptides.

- 35 -

11. Use of a beta-secretase inhibitor according to any of claims 1 to 5 in the manufacture of a pharmaceutical agent for the treatment or prevention of conditions selected from the group consisting of Alzheimer's disease, Down syndrome, cerebral amyloid angiopathy, 5 Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D) and other degenerative dementia characterized by beta-amyloid deposits.
12. A method of treating or preventing a disease characterized by beta-amyloid deposits such as Alzheimer's disease by modulating the activity of the beta-amyloid converting enzyme, comprising administering to a patient in need of such treatment a compound according to claims 1 to 5, or a pharmaceutically acceptable salt 10 thereof.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/00504

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/415 A61K31/44 A61K31/505 A61K31/42 A61K31/13

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | DATABASE CHEMCATS 'Online!<br>CAS-Registry Number 312528-59-9,<br>1 July 2001 (2001-07-01)<br>CATALOG: "Compounds for screening"<br>XP002240135<br>abstract<br>--- | 1-4                   |
| X          | PATENT ABSTRACTS OF JAPAN<br>, 29 March 1996 (1996-03-29)<br>& JP 07 309822 A (ASAHI),<br>28 November 1995 (1995-11-28)<br>abstract<br>---<br>-/-                  | 1,3,4,6,<br>8-12      |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 May 2003

Date of mailing of the international search report

22/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Loher, F

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/00504

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | "New therapeutic patents for Alzheimer's disease"<br>EXPERT OPINION ON THERAPEUTIC PATENTS 1998<br>UNITED KINGDOM,<br>vol. 8, no. 12, 1998, pages 1751-1757,<br>XP002240134<br>ISSN: 1354-3776<br>especially compound 2, disclosed on page<br>1753<br>---  | 1,3,4,6,<br>8-12      |
| X          | DOVEY H F ET AL: "Functional<br>gamma-secretase inhibitors reduce<br>beta-amyloid peptide levels in brain."<br>JOURNAL OF NEUROCHEMISTRY,<br>vol. 76, no. 1, January 2001 (2001-01),<br>pages 173-181, XP001147446<br>ISSN: 0022-3042<br>especially compound 7<br>figure 1<br>figure 8<br>page 180, last sentence<br>--- | 1,3,4,6,<br>8-12      |
| X          | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 942642,<br>28 November 1988 (1988-11-28)<br>XP002240136<br>abstract<br>---  | 1,3-6                 |
| X          | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 2371721,<br>5 July 1989 (1989-07-05)<br>XP002240137<br>abstract<br>---  | 1,3-6                 |
| X          | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 3310160,<br>15 February 1990 (1990-02-15)<br>XP002240138<br>abstract<br>---   | 1,3-6                 |
| X          | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 4449197,<br>2 December 1991 (1991-12-02)<br>XP002240139<br>abstract<br>---  | 1,3-6                 |
| X          | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 3467270,<br>15 February 1990 (1990-02-15)<br>XP002240140<br>abstract<br>---   | 1,3-6                 |
|            |  | -/-                   |

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/00504

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| X        | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 2136980,<br>29 Juné 1989 (1989-06-29)<br>XP002240141<br>abstract<br>---  | 1, 3-6                |
| X        | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 2055344,<br>29 June 1989 (1989-06-29)<br>XP002240142<br>abstract<br>---  | 1, 3-6                |
| X        | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 1916474,<br>29 June 1989 (1989-06-29)<br>XP002240143<br>abstract<br>---  | 1, 3-6                |
| X        | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 5609770,<br>12 February 1993 (1993-02-12)<br>XP002240144<br>abstract<br>---  | 1, 3-6                |
| X        | DATABASE BEILSTEIN 'Online!<br>Beilstein Registry Number 2665065,<br>XP002240145<br>abstract<br>---   | 1, 3-6                |
| X, P     | DATABASE CHEMCATS 'Online!<br>CAS-Registry Number 382597-52-6,<br>2 January 2003 (2003-01-02)<br>CATALOG: "Ambinter: Exploratory library"<br>XP002240186<br>abstract<br>----- | 1, 3, 4               |

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

---

Continuation of Box I.1

Rule 39.1(iv) PCT – Method for treatment of the human or animal body by therapy

---

Continuation of Box I.2

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been restricted to

- a) the compounds ID1-ID7 disclosed in claim 2
- b) compounds with alleged beta secretase inhibitory action which fall within the scope of formula (I), i.e. use claims 8 to 12.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/00504

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

## Information on patent family members

International Application No

PCT/EP 03/00504

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| JP 07309822                            | A 28-11-1995     | NONE                    |                  |